Work

Two randomized open-label studies of daratumumab (DARA) plus standard of care treatment versus standard of care alone in patients with previously untreated multiple myeloma (MM) ineligible for high-dose therapy: 54767414MMY3007 (Alcyone) and 54767414MMY3008 (Maia)

Year: 2015

Type: article

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/j.clml.2015.07.600

Authors: T. Facon, M. Cavo, A. Jakubowiak, J. San Miguel, S. Kumar, R.Z. Orlowski, S. Usmani, A. Palumbo, R. Bandekar, J. Wang, W. Crist, L. O’Rourke, R. Carson, K. Wu, M. Qi, T. Ahmadi, M.V. Mateos

Institutions: Centre Hospitalier Universitaire de Lille, University of Bologna, University of Chicago, Clinica Universidad de Navarra, Mayo Clinic, The University of Texas MD Anderson Cancer Center, Carolinas Healthcare System, Levine Cancer Institute, University of Turin, Instituto de Investigación Biomédica de Salamanca

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2297235805

FWCI: 0.227

Cites:

Cited by: 3

Related to: 10